Looking for broad exposure to the Healthcare - Pharma segment of the equity market? You should consider the VanEck Pharmaceutical ETF (PPH), a passively managed exchange traded fund launched on ...

Experienced and novice investors alike may want to consider pharmaceutical exchange-traded funds (ETFs) as a way to gain ...

Learn how LABD delivers -3x daily biotech exposure, why it’s down 99.98% since inception, and when it fits short-term trades.

Health care stocks have been under the weather for most of 2025, but key sector fund vital signs look promising.

Triple-leveraged ETFs aren’t for everyone, but if you believe biotech is about to break out, Direxion Daily S&P Biotech Bull ...

UNH earnings reveal rising margin pressure from Medicare Advantage; investors may look to these healthcare ETFs for ...

A smart beta exchange traded fund, the State Street SPDR S&P Pharmaceuticals ETF (XPH) debuted on 06/19/2006, and offers broad exposure to the Health Care ETFs category of the market. What Are Smart ...

The VanEck Pharmaceutical ETF (NYSEARCA:PPH) has surged 26% over the past year, driven almost entirely by the weight-loss ...

Shares Biotechnology ETF (IBB) is a BUY: large-cap biotech stability, M&A and AI catalysts, and 2026 upside. Read the full analysis here.

The VanEck Pharmaceutical exchange-traded fund is on a strong run this week as news of Pfizer's deal with the Trump administration helped boost pharmaceutical stocks. The ETF was up 1.1% at $94.36 in ...

The iShares Biotechnology ETF tracks U.S. biotech firms, offering exposure to companies advancing research, development, and innovation.